🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

BCYC BCYC

Company Profile ↓
$3.97
-50.68% 1Y
P/E-1.26
52W High$8.87
52W Low$3.86
EPS (TTM)$-3.16

Company Overview

BCYC (BCYC) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 71.2% CAGR over the past five years.

Recent Developments

  • Dec 2025 Revenue of $72.59M (+105.8% YoY); net profit $-218.96M.
  • Trailing 12 Months Year-on-year growth — revenue +105.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR 71.2%, profit CAGR -31.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:71.21%
1 Year:105.77%

Compounded Profit Growth

5 Years:-31.42%
1 Year:-

Stock Price Performance

1 Year:-50.68%
6 Months:-33.83%
3 Months:-18.98%
1 Month:-9.36%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 2% of range
$3.86 $8.87
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)44.47 · Neutral
Price Performance
1M-9.36%
3M-18.98%
6M-33.83%
1Y-50.68%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 71.2% over 5 years.

CONS

  • Earnings shrank at -31.4% CAGR over 5 years.
  • Trading 55.2% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-1.26
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
71.21%
Profit 5Y
-31.42%
Revenue (YoY)
105.77%
Earnings (YoY)
-

Profitability & Returns

ROCE
-37.50%
ROE
-35.90%
ROA
-30.51%
Profit Margin
-
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-0.72
EPS (TTM)
$-3.16

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
$606.58M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
4.47%
Chg in Prom Hold
-
FII / Inst Holding
73.90%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$72.59M
EBITDA
$-212.18M
Free Cash Flow
$-252.03M
Operating Cash Flow
$-249.68M
Shares Outstanding
-
Gross Margin
-
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 2.81M1.66M1.61M1.06M6.38M1.52M614.00K5.28M1.13M1.57M3.84M3.85M1.81M1.78M4.33M3.86M4.38M3.04M4.90M11.40M5.35M19.53M9.36M2.68M-9.98M2.92M11.73M47.95M887.00K629.00K
Cost of Revenue -------------------------------
Gross Profit -------------------------------
Operating Expenses --------------------------90.27M77.44M72.61M66.48M55.26M
Operating Income --4.96M-6.36M--3.29M-7.99M-10.25M--11.64M-12.58M-10.68M--16.02M-17.28M-14.29M-27.38M-27.30M-29.76M-41.80M-43.11M-50.80M-31.72M-46.65M-63.85M--70.20M-87.35M-65.71M-24.66M-65.59M-54.63M
EBITDA ---------------------------77.43M-57.09M-17.50M-59.48M-49.13M
Interest Expense --------------------------54.00K44.00K57.00K48.00K44.00K
Pretax Income ---------------------------79.18M-58.90M-18.89M-60.65M-50.24M
Tax Provision ---------------------------231.00K205.00K1.26M172.00K90.00K
Net Income -2.53M-4.98M-7.69M-6.64M-6.50M-10.22M-9.48M-4.41M-11.32M-12.12M-10.14M-17.43M-16.19M-17.91M-14.68M-27.56M-26.83M-28.35M-39.06M-42.60M-49.90M-26.56M-39.81M-50.80M--60.75M-78.95M-59.10M-20.15M-60.83M-50.33M
Diluted EPS ----------0.67-0.52--0.73-0.74-0.59-0.93-0.90-0.96-1.30-1.41-1.26-0.62-0.77-0.74--0.88-1.14-0.85-0.29-0.87-0.72
R&D Expense -4.92M5.64M-6.28M6.54M6.08M-7.77M7.96M7.36M-9.69M11.72M10.51M14.28M19.85M22.75M32.21M39.72M39.87M34.86M40.06M48.27M-59.06M71.03M58.43M-48.90M41.16M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 2.06M7.14M13.80M10.39M11.70M14.46M26.98M35.27M72.59M
Cost of Revenue ---------
Gross Profit ---------
Operating Expenses -----131.12M216.92M244.43M320.30M
Operating Income -16.21M-21.75M-26.30M-51.96M-65.62M-116.65M-189.95M-209.15M-247.72M
EBITDA ------107.21M-169.40M-164.89M-212.18M
Interest Expense -----3.34M3.26M1.73M206.00K
Pretax Income ------114.24M-179.21M-173.80M-218.81M
Tax Provision ------1.52M1.46M-4.76M152.00K
Net Income -16.26M-21.85M-30.61M-51.01M-66.82M-112.72M-180.66M-169.03M-218.96M
Diluted EPS ---2.77-2.66-2.67-3.80-5.08-2.90-3.16
R&D Expense 11.87M20.76M25.54M33.15M44.88M81.61M156.50M172.97M240.28M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --81.63M110.19M161.15M479.79M410.61M595.34M956.87M717.60M
Total Equity -33.80M-47.18M-69.83M93.20M95.46M346.25M270.78M370.93M793.06M609.98M
Cash & Equivalents --000438.68M339.15M526.42M879.52M628.11M
Long Term Debt ----14.51M29.87M30.32M30.70M--
Total Liabilities --29.25M17.00M65.69M133.54M139.83M224.41M163.81M107.62M
Current Liabilities --8.93M8.82M23.13M36.24M53.34M69.54M67.23M56.98M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -1.42M-26.08M-28.61M-17.79M-14.79M-86.11M-60.63M-164.72M-249.68M
Investing Cash Flow -1.11M-1.19M-1.55M-1.20M-2.03M-18.99M-2.93M-1.24M-2.35M
Financing Cash Flow 57.88M25.43M58.44M62.84M320.73M6.69M250.03M519.75M-131.00K
Capital Expenditure -1.11M-1.19M-1.55M-1.20M-2.03M-18.99M-2.93M-1.24M-2.35M
Free Cash Flow -2.53M-27.26M-30.17M-18.99M-16.82M-105.10M-63.56M-165.96M-252.03M

Ratios (Annual)

Figures in %.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ---------
Operating Margin % -787.0%-304.7%-190.6%-500.1%-561.0%-806.6%-704.1%-592.9%-341.3%
Net Margin % -789.3%-306.1%-221.8%-491.0%-571.2%-779.3%-669.7%-479.2%-301.7%
ROE % 34.5%31.3%-32.8%-53.4%-19.3%-41.6%-48.7%-21.3%-35.9%
ROCE % --29.9%-25.9%-37.6%-14.8%-32.7%-36.1%-23.5%-37.5%

Shareholding Pattern

Insiders
4.47%
Institutions
73.90%
Public Float
77.36%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BCYC

Yahoo Finance hu, 30 Jul 2026

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

CAMBRIDGE, England & BOSTON, July 30, 2026--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today r…

Yahoo Finance Fri, 24 Jul 2026

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading

European equities traded in the US as American depositary receipts were tracking higher late Friday

Yahoo Finance Fri, 03 Jul 2026

Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?

Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.…

Yahoo Finance ue, 30 Jun 2026

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

European equities traded in the US as American depositary receipts were heading higher late Tuesday

Yahoo Finance Wed, 17 Jun 2026

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

European equities traded in the US as American depositary receipts were sharply higher late Wednesda

Yahoo Finance ue, 16 Jun 2026

European Equities Traded in the US as American Depositary Receipts Slightly Higher in Tuesday Trading

European equities traded in the US as American depositary receipts were marginally higher Tuesday mo

BCYC — Frequently Asked Questions

What is the current share price of BCYC?

As of 2026-08-05 17:25 PDT, BCYC trades at $3.97 on NASDAQ/NYSE. Its 52-week range is $3.86 to $8.87.

What is the P/E ratio of BCYC?

BCYC trades at a trailing price-to-earnings (P/E) ratio of -1.26.

What is the return on equity (ROE) of BCYC?

BCYC has a return on equity (ROE) of -35.90%. Its return on capital employed (ROCE) is -37.50%.

Is BCYC a good stock to buy?

This page provides a data-driven analysis of BCYC, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space